Kansas City Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO
KANSAS CITY, Kan., July 25, 2022 (GLOBE NEWSWIRE) —
Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chief Financial Officer Louis G. Van Horn has been named a 2022 Chief Financial Officer of the Year by the Kansas City Business Journal. This prestigious award recognizes Van Horn’s exceptional leadership and contributions to Cingulate’s success.
Van Horn, a seasoned business executive with a wealth of experience in finance and strategic planning, played a crucial role in Cingulate’s journey to its highly successful IPO in 2021. His strategic financial oversight and innovative approach to capital management were instrumental in positioning the company for growth and profitability in the competitive biopharmaceutical industry.
Kansas City Business Journal Names Cingulate’s Louis G. Van Horn a 2022 Chief Financial Officer of the Year
Van Horn’s leadership at Cingulate has been recognized not only by the Kansas City Business Journal but also by his peers in the industry. This award is a testament to his dedication, expertise, and vision for driving the company’s financial success and achieving its long-term goals.
As Cingulate continues to advance its pipeline of next-generation pharmaceutical products, Van Horn’s strategic financial acumen will be instrumental in navigating the company through the complex challenges and opportunities in the biopharmaceutical landscape. His leadership and contributions will play a key role in driving Cingulate’s future growth and innovation.
How This Will Affect Me
As an employee or shareholder of Cingulate Inc., Louis G. Van Horn’s recognition as a 2022 Chief Financial Officer of the Year by the Kansas City Business Journal is a positive sign of the company’s financial stability and growth potential. His leadership will likely continue to drive the company’s success and create opportunities for career advancement and financial growth for employees and shareholders alike.
How This Will Affect the World
Van Horn’s expertise and contributions to Cingulate’s success have the potential to impact the world by advancing the development and delivery of innovative pharmaceutical products that can improve global healthcare outcomes. By leading the financial strategy of a cutting-edge biopharmaceutical company, Van Horn is playing a role in shaping the future of healthcare and making a positive difference in the lives of patients worldwide.
Conclusion
Chief Financial Officer Louis G. Van Horn’s recognition by the Kansas City Business Journal as a 2022 Chief Financial Officer of the Year highlights his exceptional leadership and contributions to Cingulate’s success. His strategic financial acumen will continue to drive the company’s growth and innovation, benefiting employees, shareholders, and the global healthcare community. Van Horn’s dedication and expertise position him as a key player in shaping the future of biopharmaceuticals and advancing healthcare worldwide.
